Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director Rana R. McKay, MD Brian Rini, MD, FASCO Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: November 18, 2021 Expired: November 17, 2022

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

Maria E. Arcila, MD Released: November 16, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the use of targeted therapies for advanced biliary tract cancer

Mark Yarchoan, MD Released: November 12, 2021